
According to a new market report published by Transparency Market Research "Renal Denervation Devices (Symplicity, EnligHTN, OneShot, V2, Paradise, TIVUS, Bullfrog, Surround Sound, Micro-Infusion, Ultrasound and Radiofrequency) Market - Global Industry Analysis, Size, Share, Growth, and Forecast, 2012 - 2021," the RDN devices market was USD 88.5 million in 2012 globally and is expected to grow to USD 1.9 billion by 2021, at a CAGR of 41.2% from 2012 to 2021. In 2012, Medtronic's Symplicity held the largest share in the global RDN devices accounting for 85.5% of the global RDN devices market. Medtronic's Symplicity is expected to face tough competition from emerging products such as Boston Scientific's (Vessix's Vascular) V2, St. Jude Medical's EnligHTN, Covidien's OneShot and ReCor Medical's Paradise.